Day: January 3, 2024

LEXINGTON, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) to expand the use of its FDA-cleared T2Candida® Panel to include pediatric testing. The T2Candida Panel is the only FDA-cleared diagnostic test able to detect sepsis-causing Candida pathogens directly from blood, in just 3-5 hours, without the need to wait days for a positive blood culture. The T2Candida Panel runs on the FDA-cleared T2Dx® Instrument and simultaneously detects five Candida species – including Candida albicans, Candida tropicalis, Candida parapsilosis, Candida krusei, and Candida glabrata. According to the U.S. Centers for...

REDWOOD CITY, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (“Coherus,” Nasdaq: CHRS), today announced that senior management will present at the upcoming 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 9:45 a.m. Pacific Time. The presentation and Q&A session will be accessible via Webcast through a link posted on the Investor Events Calendar section of the Coherus website: https://investors.coherus.com/upcoming-events. This webcast will be available for replay until February 9, 2024. Coherus Contact Information:Jami Taylor, Head of Investor RelationsCoherus Biosciences, Inc.IR@coherus.com  

The Management Board of joint stock company “Latvijas Gāze”, registration number: 40003000642, legal address:, Aristida Briana street 6, Riga, LV-1001, Latvia (hereinafter – the “Company”), hereby convenes and announces that the Extraordinary Meeting of Shareholders of the Company will take place on 22 February 2024 at 10:00 at Vagonu street 20, Riga, Latvia.   The agenda:On the new wording of the Articles of Association of the joint stock company “Latvijas Gāze” and on the selection of the central securities depository in which to register the shares of the joint stock company “Latvijas Gāze”. Election of the Supervisory Council and determination of remuneration for the Supervisory Council. Election of the Audit Committee and determination of remuneration for the Audit Committee.  The Management Board of the...

Dan Peisert Stepping Down as CEO Board member Heather Mason Appointed Interim CEO LAKE FOREST, Ill., Jan. 03, 2024 (GLOBE NEWSWIRE) — Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company that acquires, commercializes and develops safe and effective therapies that make a difference in the lives of patients, announced today that Dan Peisert is stepping down as the Company’s Chief Executive Officer. The Board has appointed Heather Mason, currently an independent director of the Company and Chair of its Nominating and Corporate Governance Committee, to serve as interim CEO as the Company conducts a search for a permanent chief executive. Peter Staple, Chairman of the Assertio Board of Directors, said, “On behalf of the Board, I would like to express our appreciation to Dan for his...

WARSAW, N.Y., Jan. 03, 2024 (GLOBE NEWSWIRE) — Financial Institutions, Inc. (NASDAQ: FISI) (the “Company”), the parent company of Five Star Bank, SDN Insurance Agency, LLC, and Courier Capital, LLC, will release results for the fourth quarter and full year ended December 31, 2023 after the market closes on January 25, 2024. Management will host an earnings conference call and audio webcast on January 26, 2024 at 8:30 a.m. Eastern Time. The call will be hosted by Martin K. Birmingham, President and Chief Executive Officer, and W. Jack Plants II, Chief Financial Officer and Treasurer. The live webcast will be available in listen-only mode on the Company’s website at www.FISI-Investors.com. Within the United States, listeners may also access the call by dialing 1-833-470-1428 and providing the access code 280151. The webcast replay...

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024, at 9:45 am PT. The live presentation will be webcast and may be accessed from the Investors section of Tenaya’s website. A replay of the webcast will be available on the Tenaya website for approximately 30 days following the conference. About Tenaya TherapeuticsTenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that...